Biogen, Ionis End ALS Program; Ionis Will Advance Angelman Asset Alone
Long-Time Partners Decide Fate Of Two Drugs
Development has ended for BIIB105 in ALS after it failed to clear a crucial biomarker and show clinical benefit. Also, Biogen opted not to advance ION582 for Angelman syndrome, so Ionis will go it alone.
